ADCs

With over ten years of experience supporting antibody drug conjugate (ADC) discovery, development and manufacturing, our multidisciplinary team has worked with a range of different antibodies, linkers and toxins to enable us to develop customised bioconjugation approaches and offer complex ADC solutions to our customers.

ADCs at Sterling

News2 min read

GlycoNex Announces Manufacturing Agreement with Sterling for GNX102-ADC Clinical Trial Production Read more

Popular in this category

News2 min read

Sterling Expands GMP ADC Manufacturing Capacity at Deeside, UK Read more

Mass spectrometry

Infographic1 min read

Measurement of ADC stability in plasma and serum via mass spectrometry analysis Read more

One pager2 min read

Antibody drug conjugation (ADC) overview Read more

Whitepaper12 min read

Applying analytical method validation to cell-based potency assays Read more

All articles

Sterling's Deeside, UK facility

News2 min read

Sterling Expands Bioanalytical Capabilities at Deeside, UK Site Read more

Mass spectrometry

One pager3 min read

Stability of ADCs in sub-cellular fractions Read more

Mass spectrometry

One pager3 min read

Stability of ADC linker payloads in sub-cellular fractions Read more

Mass spectrometry

One pager3 min read

Stability of ADC toxins in sub-cellular fractions Read more

HPAPI capabilities at Germantown, Wisconsin

News2 min read

Sterling Expands HPAPI Capabilities to Further Strengthen Integrated ADC Services Read more

Sterling's Deeside, Wales antibody drug conjugation facility, UK

Spotlight2 min read

Facility overview video: Deeside, UK Read more

One pager2 min read

Monitoring oxidative stress of biologics Read more

Monitoring pH stress of biologics

One pager2 min read

Monitoring pH stress of biologics Read more

Poster Presentation2 min read

Optimising and validating a cell based assay for SDE-100 exemplar batch Read more

Next Page »

Explore more

All ADCs API Development API Manufacturing Analytical Services Drug Discovery Facilities News PDMO People Peptides Sustainability Technologies

Sign up for updates

Be the first to see the latest articles and updates from industry leaders, delivered straight to your inbox

Name(Required)

Email(Required)

Company Name(Required)

This field is hidden when viewing the form

Prospect Source

Please click here for our privacy policy

This field is for validation purposes and should be left unchanged.

Service. Passion. Science.

PDMO^® is registered in the U.S. Patent and Trademark Office.

PDMO^® is a registered trademark of Sterling Pharma Solutions Limited (EUIPO and UKIPO). All rights reserved.

Sterling Pharma Solutions Limited. Registration number: 05712796. Registered office address: Sterling Place, Dudley, Cramlington, Northumberland NE23 7QG. Registered in England.